Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas

Concomitant chemoradiotherapy for refractory or chemoresistant-relapsed lymphoma induced high hematologic toxicity, but seemed adequate for controlling local bulky tumor masses. No toxicity-related death was observed.